FDA says no adcomm planned for Biogen, Sage's depression drug

Biogen (NASDAQ:BIIB) and Sage Therapeutics (NASDAQ:SAGE) said the U.S. Food and Drug Administration (FDA) currently does not plan to hold an advisory committee meeting to discuss an application seeking approval of oral medicine zuranolone to treat major depressive disorder (MDD) and postpartum depression (PPD).